/Bill Langbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

By |2019-03-25T11:45:49-04:00March 25th, 2019|Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology|

One of the strongest performing biopharmaceutical stocks this year is [...]

ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies

By |2019-01-22T10:10:21-04:00January 22nd, 2019|Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|

SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]

Verona (VRNA) Talks Up The Long View Following Phase II Setback

By |2019-03-07T14:59:36-04:00January 16th, 2019|Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]

Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2

By |2019-01-22T10:10:46-04:00January 2nd, 2019|Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|

SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]